Tevogen Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement Tevogen Bio Holdings Inc. Announcement WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on…

Frontier Group Holdings, Inc. (NASDAQ:ULCC) Q3 2024 Earnings Conference Call October 29, 2024 11:30 AM ET Hey there, fellow investors and aviation enthusiasts! Today we’re diving deep into the exciting world of Frontier Group Holdings as we explore their Q3 2024 Earnings Conference Call. Grab a cup of coffee, put on your thinking caps, and…

IPG Photonics Corporation (NASDAQ:IPGP) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants: Eugene Fedotoff – Senior Director of Investor Relations Mark Gitin – Chief Executive Officer Timothy Mammen – Senior Vice President and Chief Financial Officer Conference Call Participants: Ruben Roy – Stifel Jim Rashidi – Needham & Company Keith…

Investors Alert: Class Action Lawsuit Against Super Micro Computer, Inc. Introduction On October 29, 2024, The Schall Law Firm issued a reminder to investors regarding a class action lawsuit against Super Micro Computer, Inc. The lawsuit accuses the company of violating certain sections of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), as…

Welcome to Zacks: Your Source for Stock Analysis Staying Ahead of the Curve with Zacks Rank System Here at Zacks, our main focus is on the proven Zacks Rank system, which places a strong emphasis on earnings estimates and estimate revisions to identify great stocks for our clients. By utilizing this data-driven approach, we are…

Discovering Hope: Longeveron’s Groundbreaking Lomecel-B Data for Alzheimer’s Disease Unveiled at CTAD24 Conference Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates with improved clinical and biomarker outcomes in mild AD. The immunomodulatory and pro-vascular effects of Lomecel-B™ in…

Partnership between Dolphin and Loti AI to Safeguard Against Unauthorized Use of Content Collaboration for Innovation and Brand Safety Dolphin, a prominent entertainment marketing and content production company, has recently joined forces with Loti AI, a renowned likeness protection technology provider. This strategic partnership aims to shield Dolphin’s clients, which include top-tier companies like 42West…